# A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions

> **NCT05397834** · PHASE1 · UNKNOWN · sponsor: **Respirent Pharmaceuticals Co Ltd.** · enrollment: 36 (actual)

## Conditions studied

- Asthma
- Bioequivalence

## Interventions

- **DRUG:** Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals
- **DRUG:** FLOVENT DISKUS

## Key facts

- **NCT ID:** NCT05397834
- **Lead sponsor:** Respirent Pharmaceuticals Co Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-05-11
- **Primary completion:** 2022-06-21
- **Final completion:** 2022-09-01
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2022-05-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05397834

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05397834, "A Bioequivalence Study Between Fluticasone Propionate 250 mcg/Blister Oral Inhalation Powder/Respirent Pharmaceuticals vs. FLOVENT DISKUS® 250 mcg/Blister Oral Inhalation Powder /GSK in Healthy Volunteers Under Fasting Conditions". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05397834. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*